Survher: A retrospective multicenter study comparing demographic and tumor characteristics of clinical trials versus clinical practice patients with HER2-positive breast cancer.
Grazia Arpino(University of Naples Federico II), Sabino De Placido, Claudio Zamagni(Policlinico S.Orsola-Malpighi), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Filippo Montemurro(Roche (Switzerland)), Antonio Nuzzo(Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente), Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Alessandra Beano(Presidio Ospedaliero), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Dario Bruzzese(University of Naples Federico II), Stefania Russo(National Center for Oncological Hadrontherapy), Mauro Truini(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Vito Lorusso, Andrea Michelotti(University of Pisa), R. Palumbo(Fondazione Salvatore Maugeri), Angelo Di Leo(Hospital of Prato), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Maria Malagoli, Francesco Schettini(Target (United States))
Cited by 0
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k